Amphastar Pharmaceuticals Files 10-Q for Q1 2025
Ticker: AMPH · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, equity, share-repurchase
Related Tickers: AMPH
TL;DR
AMPH Q1 2025 10-Q filed. Equity details and buyback info updated.
AI Summary
Amphastar Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including common stock, retained earnings, and additional paid-in capital as of March 31, 2025. It also references share repurchase plans initiated in November 2014.
Why It Matters
This filing provides investors with an update on Amphastar's financial health and equity structure for the first quarter of 2025, including details on share repurchases.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- Q1 2025 — Reporting Period (First quarter of 2025 financial data)
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of the reporting period
- November 2014 (date) — Date of share repurchase plan initiation
FAQ
What were the total assets and liabilities as of March 31, 2025?
The provided excerpt does not contain specific figures for total assets and liabilities.
What was Amphastar's net income for the first quarter of 2025?
The excerpt does not specify the net income for the first quarter of 2025.
How much was repurchased under the November 2014 plan during Q1 2025?
The excerpt indicates activity related to the November 2014 share repurchase plan for the period of January 1, 2025, to March 31, 2025, but does not provide a specific dollar amount for repurchases during this period.
What is the current status of Amphastar's common stock as of March 31, 2025?
As of March 31, 2025, Amphastar Pharmaceuticals, Inc. had common stock, retained earnings, additional paid-in capital, and accumulated other comprehensive income, with treasury stock also noted.
Does the filing mention any new debt or significant capital expenditures?
The filing references 'LongTermDebtAndCapitalLeaseObligations' but does not provide specific details or amounts within this excerpt.
From the Filing
0001297184-25-000029.txt : 20250508 0001297184-25-000029.hdr.sgml : 20250508 20250508162418 ACCESSION NUMBER: 0001297184-25-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 25926641 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 10-Q 1 amph-20250331x10q.htm 10-Q Amphastar Pharmaceuticals, Inc._2025-03-31 http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations http://fasb.org/us-gaap/2024#LongTermDebtAndCapitalLeaseObligations 0 0 0 0 0 0 0 Amphastar Pharmaceuticals, Inc. --12-31 false 0001297184 2025-03-31 Q1 0 0 0 0 0 true false false false 0 0 0 0 0 0 0 0001297184 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001297184 amph:November2014ShareRepurchasePlanMember 2025-01-01 2025-03-31 0001297184 amph:November2014ShareRepurchasePlanMember 2024-01-01 2024-03-31 0001297184 amph:November2014ShareRepurchasePlanMember 2024-11-30 0001297184 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001297184 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001297184 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2025-03-31 0001297184 us-gaap:RetainedEarningsMember 2025-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2024-12-31 0001297184 us-gaap:RetainedEarningsMember 2024-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001297184 us-gaap:TreasuryStockCommonMember 2024-03-31 0001297184 us-gaap:RetainedEarningsMember 2024-03-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001297184 us-gaap:TreasuryStockCommonMember 2023-12-31 0001297184 us-gaap:RetainedEarningsMember 2023-12-31 0001297184 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001297184 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001297184 amph:EmployeeStockPurchasePlan2014Member 2025-03-31 0001297184 amph:The2015EquityIncentivePlanMember 2025-03-31 0001297184 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:TotalNetRevenuesByProductMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:OtherProductsMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:LidocaineMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:GlucagonMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:EpinephrineMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember amph:BaqsimiMember 2025-01-01 2025-03-31 0001297184 amph:AnpMember amph:ResearchAndDevelopmentServicesMember 2025-01-01 2025-03-31 0001297184 amph:AnpMember amph:NanjingHanxinPharmaceuticalTechnologyCoLtdMember 2025-01-01 2025-03-31 0001297184 us-gaap:ProductMember 2025-01-01 2025-03-31 0001297184 country:US 2025-01-01 2025-03-31 0001297184 country:FR 2025-01-01 2025-03-31 0001297184 country:CN 2025-01-01 2025-03-31 0001297184 amph:GenreachMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegmentMember 2025-01-01 2025-03-31 0001297184 amph:FinishedPharmaceuticalProductsSegme